Recombinant insulin glargine biosimilar (Biogenomics)

重组甘精胰岛素生物类似药 (Biogenomics)

Report date: 2025/05/06 15:48:38

Base Information

Drug NameRecombinant insulin glargine biosimilar (Biogenomics)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant hormoneBiologics > Biosimilar
Mechanisms of ActionInsulin receptor agonists
TargetsInsulin receptor
Therapy Area/IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIndia
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesBiogenomics
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBiogenomics
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1

Other Information

ATC CodeN/A
Related LinksN/A